Fulgent Genetics Reports Q1 2026 Earnings Call Summary

Fulgent Genetics reported a $6 million sequential revenue decline due to in-house testing transition by its largest customer. The company acquired Bako Diagnostics and StrataDx, expanded market presence, and introduced an AI tool for dermatopathology. Management reiterated full-year 2026 revenue guidance at $350 million.

By Moby Intelligence May 1, 2026 3 min read · Yahoo Finance · May 1, 2026, 20:46 UTC

Fulgent Genetics Reports Q1 2026 Earnings Call Summary

Tickers: $FLGT

Topics: acquisitions financial performance strategic initiatives technology innovation

Read the full article at Yahoo Finance

More World news

SpaceX Partners with Qualcomm to Launch Starlink Mobile Cellular Service Motley Fool · November 12, 2026, 15:21 UTC
Blast Resources Appoints Andy Yackulic as CEO to Lead Uranium Exploration PR Newswire · November 12, 2026, 15:26 UTC
FMC Corporation Shares Decline 13% in Thursday Trading Seeking Alpha · November 12, 2026, 15:22 UTC
U.S. Stock Indices Decline Following Nvidia CEO Jensen Huang's Resignation Seeking Alpha · November 12, 2026, 15:23 UTC
EY Report Outlines Three Fundamental Shifts Required for Future-Ready Health Systems by 2040 PR Newswire · November 12, 2026, 15:24 UTC
ProLift Garage Doors Expands Franchise Services and Support Initiatives PR Newswire · November 12, 2026, 15:24 UTC
Pomerantz Law Firm Investigates Cerebras Systems Inc. Over Potential Securities Fraud PR Newswire · November 12, 2026, 15:25 UTC
CEZ Reports 9M Revenue Growth and 24% Increase in Net Income Seeking Alpha · November 12, 2026, 15:05 UTC
BlueMatrix Completes Acquisition of AI-Enabled Research Platform Aiera PR Newswire · November 12, 2026, 15:15 UTC
U.S. Lawmakers Respond to Jensen Huang's Resignation as Nvidia CEO Seeking Alpha · November 12, 2026, 15:12 UTC